Status:

WITHDRAWN

A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

Lead Sponsor:

Siemens Molecular Imaging

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after \[F-18\] HX4 injection. This study will provide guidance for future studies ...

Detailed Description

Each consented patient will have a single administration of \[F-18\]HX4 and will immediately undergo one list mode PET/CT imaging session lasting 60 minutes followed by three additional list mode PET/...

Eligibility Criteria

Inclusion

  • Patient is \>18 years and male or female of any race / ethnicity.
  • Patient or patient's legally acceptable representative provides written inform consent Patient is willing and able to comply with protocol procedures.
  • Patient has newly diagnosed histologically confirmed squamous cell carcinoma of the head and/or neck whose primary origin is from the oral cavity, oropharynx, hypopharynx, larynx or nasopharynx.
  • Patient is scheduled to have or already has had a clinical \[F-18\]FDG PET/CT scan prior (recommended to be within 14 days prior) to the \[F-18\]HX4 PET/CT scan.
  • Patient has a primary tumor ≥ 2.0 cm in longest axis measured by CT or MR; or lymph node ≥ 2.0 cm in shortest axis measured by CT or MR if primary tumor \< 2 cm on CT or MR; CT may be part of required \[F-18\]FDG PET/CT scan or a separate pre-surgery CT scan.
  • Patient is scheduled to undergo complete tumor resection within 7 days for his/her cancer care after the \[F-18\]HX4 PET/CT scan is performed.
  • Patient has not had nor will have neoadjuvant treatment, including radiation and chemotherapy, prior to patient's planned tumor resection.

Exclusion

  • Female patient is pregnant or nursing.
  • Patient is not capable of remaining still for duration of imaging procedure (\~ 4 hours).
  • Patient has undergone an investigative, radioactive research procedure within 7 days prior to study participation, or is scheduled to undergo such a procedure during the study participation period.
  • Patient has chronic renal function failure or is on renal dialysis
  • Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data.

Key Trial Info

Start Date :

September 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2013

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01506427

Start Date

September 1 2012

End Date

June 1 2013

Last Update

December 17 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Iowa Medical Center

Iowa City, Iowa, United States, 52242